These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 26331791)

  • 1. Pharmacokinetics of venlafaxine enantiomers and their metabolites in psoriasis patients.
    Godoy AL; Rocha A; da Silva Souza C; Lanchote VL
    J Clin Pharmacol; 2016 May; 56(5):567-75. PubMed ID: 26331791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nifedipine Does Not Alter the Pharmacokinetics of Venlafaxine Enantiomers in Healthy Subjects Phenotyped for CYP2D6, CYP2C19, and CYP3A.
    Tozatto E; Benzi JRL; Rocha A; Coelho EB; Lanchote VL
    J Clin Pharmacol; 2021 Mar; 61(3):319-327. PubMed ID: 32974907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of CYP2D6 genotype on the disposition of the enantiomers of venlafaxine and its major metabolites in postmortem femoral blood.
    Kingbäck M; Karlsson L; Zackrisson AL; Carlsson B; Josefsson M; Bengtsson F; Ahlner J; Kugelberg FC
    Forensic Sci Int; 2012 Jan; 214(1-3):124-34. PubMed ID: 21840145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2D6*10 polymorphism and the enantioselective O-desmethylation of S-(+)- and R-(-)-venlafaxine in Japanese psychiatric patients.
    Sasaki T; Yasui-Furukori N; Komahashi-Sasaki H; Shinozaki M; Hayashi Y; Kato K; Inoue Y; Tsuchimine S; Watanabe T; Sugawara N; Shimoda K
    Basic Clin Pharmacol Toxicol; 2021 May; 128(5):677-685. PubMed ID: 33470005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes.
    Jiang F; Kim HD; Na HS; Lee SY; Seo DW; Choi JY; Ha JH; Shin HJ; Kim YH; Chung MW
    Psychopharmacology (Berl); 2015 Jun; 232(11):1899-909. PubMed ID: 25510856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring venlafaxine pharmacokinetic variability with a phenotyping approach, a multicentric french-swiss study (MARVEL study).
    Lloret-Linares C; Daali Y; Chevret S; Nieto I; Molière F; Courtet P; Galtier F; Richieri RM; Morange S; Llorca PM; El-Hage W; Desmidt T; Haesebaert F; Vignaud P; Holtzmann J; Cracowski JL; Leboyer M; Yrondi A; Calvas F; Yon L; Le Corvoisier P; Doumy O; Heron K; Montange D; Davani S; Déglon J; Besson M; Desmeules J; Haffen E; Bellivier F
    BMC Pharmacol Toxicol; 2017 Nov; 18(1):70. PubMed ID: 29115994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers.
    Fukuda T; Yamamoto I; Nishida Y; Zhou Q; Ohno M; Takada K; Azuma J
    Br J Clin Pharmacol; 1999 Apr; 47(4):450-3. PubMed ID: 10233212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting.
    Reis M; Lundmark J; Björk H; Bengtsson F
    Ther Drug Monit; 2002 Aug; 24(4):545-53. PubMed ID: 12142641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of CYP2D6 and CYP2C19 genotypes on venlafaxine metabolic ratios and stereoselective metabolism in forensic autopsy cases.
    Karlsson L; Zackrisson AL; Josefsson M; Carlsson B; Green H; Kugelberg FC
    Pharmacogenomics J; 2015 Apr; 15(2):165-71. PubMed ID: 25245581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine.
    Lindh JD; Annas A; Meurling L; Dahl ML; AL-Shurbaji A
    Eur J Clin Pharmacol; 2003 Sep; 59(5-6):401-6. PubMed ID: 12898080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of CYP2D6 Genotypes on Venlafaxine Metabolism in Japanese Psychiatric Patients With Depression.
    Komahashi-Sasaki H; Yasui-Furukori N; Sasaki T; Shinozaki M; Hayashi Y; Kato K; Inoue Y; Tsuchimine S; Watanabe T; Sugawara N; Shimoda K
    Ther Drug Monit; 2021 Oct; 43(5):681-687. PubMed ID: 33306568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
    Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI
    J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele.
    Hermann M; Hendset M; Fosaas K; Hjerpset M; Refsum H
    Eur J Clin Pharmacol; 2008 May; 64(5):483-7. PubMed ID: 18214456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype.
    Mannheimer B; Haslemo T; Lindh JD; Eliasson E; Molden E
    Ther Drug Monit; 2016 Feb; 38(1):127-34. PubMed ID: 26418700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.
    Shams ME; Arneth B; Hiemke C; Dragicevic A; Müller MJ; Kaiser R; Lackner K; Härtter S
    J Clin Pharm Ther; 2006 Oct; 31(5):493-502. PubMed ID: 16958828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes--focus on venlafaxine and O-desmethylvenlafaxine.
    Kandasamy M; Srinivas P; Subramaniam K; Ravi S; John J; Shekar R; Srinivas N; Thangam S
    Eur J Clin Pharmacol; 2010 Sep; 66(9):879-87. PubMed ID: 20446083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects.
    Teng R; Kujacic M; Hsia J
    Clin Ther; 2014 Sep; 36(9):1217-25. PubMed ID: 25069798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine.
    Kuzin M; Schoretsanitis G; Haen E; Stegmann B; Hiemke C; Gründer G; Paulzen M
    Clin Pharmacokinet; 2018 Jun; 57(6):729-737. PubMed ID: 28866861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.
    Lessard E; Yessine MA; Hamelin BA; O'Hara G; LeBlanc J; Turgeon J
    Pharmacogenetics; 1999 Aug; 9(4):435-43. PubMed ID: 10780263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversible cardiac dysfunction after venlafaxine overdose and possible influence of genotype and metabolism.
    Castanares-Zapatero D; Gillard N; Capron A; Haufroid V; Hantson P
    Forensic Sci Int; 2016 Sep; 266():e48-e51. PubMed ID: 27328779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.